Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study

BACKGROUND: Abacavir/lamivudine and tenofovir/emtricitabine fixed-dose combinations are commonly used first-line antiretroviral therapies, yet few studies have comprehensively compared their safety profiles. METHODS: Forty-eight-week data are presented from this multicenter, randomized, open-label s...

ver descrição completa

Detalhes bibliográficos
Autor principal: Post, F (author)
Outros Autores: Moyle, G (author), Stellbrink, H (author), Domingo, P (author), Podzamczer, D (author), Fisher, M (author), Norden, A (author), Cavassini, M (author), Rieger, A (author), Khuong-Josses, MA (author), Branco, T (author), Pearce, H (author), Givens, N (author), Vavro, C (author), Lim, M (author)
Formato: article
Idioma:eng
Publicado em: 2011
Assuntos:
Infecção por HIV
Antiretrovirais
HIV-1
ASSERT Study
Texto completo:http://hdl.handle.net/10400.10/412
País:Portugal
Oai:oai:repositorio.hff.min-saude.pt:10400.10/412

Texto Completo

http://hdl.handle.net/10400.10/412

Registos relacionados